@article {10832, title = {Photobiomodulation at Multiple Wavelengths Differentially Modulates Oxidative Stress and .}, journal = {Oxid Med Cell Longev}, volume = {2018}, year = {2018}, month = {2018}, pages = {6510159}, abstract = {

Photobiomodulation (PBM) is emerging as an effective strategy for the management of multiple inflammatory conditions, including oral mucositis (OM) in cancer patients who receive chemotherapy or radiotherapy. Still, the poor understanding of the mechanisms by which the light interacts with biological tissues and the heterogeneity of light sources and protocols employed worldwide significantly limits its applicability. Reactive oxygen species (ROS) are massively generated during the early phases of OM and play a major role in the pathogenesis of inflammation in general. Here, we report the results of a clinical and experimental study, aimed at evaluating the effect of laser light at different wavelengths on oxidative stress in oncologic patients suffering from OM and in two cell types abundantly present within the inflamed oral mucosa, neutrophil polymorphonuclear (PMN) granulocytes, and keratinocytes. In addition to standard ROS detection methods, we exploited a roGFP2-Orp1 genetically encoded sensor, allowing specific, quantitative, and dynamic imaging of redox events in living cells in response to oxidative stress and PBM. We found that the various wavelengths differentially modulate ROS production. In particular, the 660 nm laser light increases ROS production when applied either before or after an oxidative stimulus. In contrast, the 970 nm laser light exerted a moderate antioxidant activity both in the saliva of OM patients and in both cell types. The most marked reduction in the levels of ROS was detected in cells exposed either to the 800 nm laser light or to the combination of the three wavelengths. Overall, our study demonstrates that PBM exerts different effects on the redox state of both PMNs and keratinocytes depending on the used wavelength and prompts the validation of a multiwavelength protocol in the clinical settings.

}, keywords = {Adult, Aged, Aged, 80 and over, Female, Humans, Keratinocytes, Lasers, Semiconductor, Low-Level Light Therapy, Male, Middle Aged, Neutrophils, Oxidation-Reduction, Oxidative Stress, Stomatitis}, issn = {1942-0994}, doi = {10.1155/2018/6510159}, author = {Rupel, Katia and Zupin, Luisa and Colliva, Andrea and Kamada, Anselmo and Poropat, Augusto and Ottaviani, Giulia and Gobbo, Margherita and Fanfoni, Lidia and Gratton, Rossella and Santoro, Massimo and Di Lenarda, Roberto and Biasotto, Matteo and Zacchigna, Serena} } @article {3484, title = {Class IV laser therapy as treatment for chemotherapy-induced oral mucositis in onco-haematological paediatric patients: a prospective study.}, journal = {Int J Paediatr Dent}, volume = {24}, year = {2014}, month = {2014 Nov}, pages = {441-9}, abstract = {

BACKGROUND: Oral mucositis is a debilitating side effect of chemotherapy. Laser therapy has recently demonstrated efficacy in the management of oral mucositis (OM).

AIM: This prospective study was conducted to evaluate the efficacy of class IV laser therapy in patients affected by OM.

DESIGN: Eighteen onco-haematological paediatric patients receiving chemotherapy and/or haematopoietic stem cell transplantation, prior to total body irradiation, affected by OM, were enrolled in this study. Patients were treated with class IV laser therapy for four consecutive days; the assessment of OM was performed through WHO Oral Mucositis Grading Objective Scale, and pain was evaluated through visual analogue scale. Patients completed a validated questionnaire, and photographs of lesions were taken during each session. Patients were re-evaluated 11 days after the first day of laser therapy.

RESULTS: All patients demonstrated improvement in pain sensation, and all mucositis was fully resolved at the 11-day follow-up visit, with no apparent side effects. Laser therapy was well tolerated with remarkable reduction in pain associated with oral mucositis after 1-2 days of laser therapy.

CONCLUSIONS: Given class IV laser therapy appears to be safe, non-invasive, and potentially effective, prospective, randomized, controlled trials are necessary to further assess efficacy and to determine optimal treatment parameters.

}, issn = {1365-263X}, doi = {10.1111/ipd.12090}, author = {Chermetz, Maddalena and Gobbo, Margherita and Ronfani, Luca and Ottaviani, Giulia and Zanazzo, Giulio A and Verzegnassi, Federico and Treister, Nathaniel S and Di Lenarda, Roberto and Biasotto, Matteo and Zacchigna, Serena} } @article {1709, title = {TRAIL shows potential cardioprotective activity.}, journal = {Invest New Drugs}, volume = {30}, year = {2012}, month = {2012 Jun}, pages = {1257-60}, abstract = {

Recent clinical trials carried out in patients with advanced cancer have shown that recombinant TRAIL administration is usually safe and well tolerated when used either alone or in association with chemotherapeutic drugs. Notably, anticancer chemotherapy can be associated to cardiomiopathy. We have here demonstrated that TRAIL (administrated as either recombinant soluble TRAIL or as AAV-TRAIL expression viral vector) reduced the development of cardiomyopathy in the ApoE(-/-) diabetic mouse model. These data suggest, for the first time, that therapeutically administration of TRAIL might have a cardioprotective effect.

}, keywords = {Animals, Apolipoproteins E, Apoptosis, Cardiotonic Agents, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Diabetic Cardiomyopathies, Fibrosis, Male, Mice, Mice, Knockout, Recombinant Proteins, TNF-Related Apoptosis-Inducing Ligand}, issn = {1573-0646}, doi = {10.1007/s10637-010-9627-8}, author = {Toffoli, Barbara and Bernardi, Stella and Candido, Riccardo and Zacchigna, Serena and Fabris, Bruno and Secchiero, Paola} }